

LIST OF TABLES

Table 1:Symptoms of AD	32
Table 2:Guidelines for the Treatment of AD	39
Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012	40
Table 4:Leading Branded Treatments for AD, 2013	45
Table 5:Product Profile - Aricept	48
Table 6:Aricept SWOT Analysis, 2013	50
Table 7:Product Profile- Exelon	52
Table 8:Exelon SWOT Analysis, 2012	55
Table 9:Product Profile - Razadyne	56
Table 10:Razadyne SWOT Analysis, 2013	59
Table 11:Product Profile- Namenda	60
Table 12:Namenda SWOT Analysis, 2013	62
Table 13:Overall Unmet Needs - Current Level of Attainment	64
Table 14:Clinical Unmet Needs - Gap Analysis, 2013	71
Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012	81
Table 16:Comparison of Therapeutic Classes in Development for AD, 2013	82
Table 17:Comparison of Therapeutic Classes in Development for AD, 2013	83
Table 18:Product Profile - Namenda XR	84
Table 19:Namenda XR SWOT Analysis, 2013	86
Table 20:Product Profile - Arimenda	87
Table 21:Arimenda SWOT Analysis, 2013	89
Table 22:Product Profile - Gammagard Liquid 10%	90
Table 23:Product Profile - Solanezumab	92
Table 24:Solanezumab SWOT Analysis, 2013	95
Table 25:Product Profile - Gantenerumab	96
Table 26:Gantenerumab SWOT Analysis, 2013	99
Table 27:Product Profile - Crenezumab	100
Table 28:Crenezumab SWOT Analysis, 2013	103
Table 29:Product Profile - TRx0237	104
Table 30:TRx0237 SWOT Analysis, 2013	106
Table 31:Product Profile - MK-8931	107
Table 32:MK-8931 SWOT Analysis, 2013	110
Table 33:Product Profile - EVP-6124	111
Table 34:EVP-6124 SWOT Analysis, 2013	113
Table 35:Product Profile - Lu AE58054	114
Table 36:Lu AE58054 SWOT Analysis, 2013	116
Table 37:Sales Forecasts (\$m) for AD in the United States, 2012-2022	119
Table 38:Key Events Impacting Sales for AD in the United States, 2012-2022	121
Table 39:AD Market in the United States - Drivers and Barriers, 2012-2022	121
Table 40:Key Launch Dates	149
Table 41:Key Patent Expirations	150

List of Figures

Figure 1: Atrophy of the Brain in AD 21

Figure 2: Key Pathological Features in AD Versus a Healthy Neuron 23

Figure 3: Non-Amyloidogenic Metabolism of APP 25

Figure 4: Amyloidogenic Metabolism of APP 26

Figure 5: Neurofibrillary Tangles 28

Figure 6: Oxidative Damage Due to Free Radicals 30

Figure 7: Strategic Competitor Assessment of the Marketed Products in AD, 2013 46

Figure 8: AD - Pipeline Drugs by Target, 2012 76

Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 82

Figure 10: Sales for AD in the United States by Drug Class, 2012-2022 120